FUSN vs. CGON, INBX, DNA, NVAX, SANA, BEAM, ADMA, NMRA, KYMR, and TARS
Should you be buying Fusion Pharmaceuticals stock or one of its competitors? The main competitors of Fusion Pharmaceuticals include CG Oncology (CGON), Inhibrx (INBX), Ginkgo Bioworks (DNA), Novavax (NVAX), Sana Biotechnology (SANA), Beam Therapeutics (BEAM), ADMA Biologics (ADMA), Neumora Therapeutics (NMRA), Kymera Therapeutics (KYMR), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "biological products, except diagnostic" industry.
CG Oncology (NASDAQ:CGON) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Fusion Pharmaceuticals received 33 more outperform votes than CG Oncology when rated by MarketBeat users. However, 80.00% of users gave CG Oncology an outperform vote while only 64.06% of users gave Fusion Pharmaceuticals an outperform vote.
In the previous week, CG Oncology had 8 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 8 mentions for CG Oncology and 0 mentions for Fusion Pharmaceuticals. CG Oncology's average media sentiment score of 1.00 beat Fusion Pharmaceuticals' score of 0.33 indicating that Fusion Pharmaceuticals is being referred to more favorably in the news media.
CG Oncology currently has a consensus price target of $63.75, indicating a potential upside of 112.64%. Fusion Pharmaceuticals has a consensus price target of $20.25, indicating a potential downside of 5.86%. Given Fusion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than Fusion Pharmaceuticals.
26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. 7.8% of Fusion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
CG Oncology has a net margin of 0.00% compared to CG Oncology's net margin of -4,136.55%. Fusion Pharmaceuticals' return on equity of 0.00% beat CG Oncology's return on equity.
CG Oncology has higher earnings, but lower revenue than Fusion Pharmaceuticals.
Summary
CG Oncology beats Fusion Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Fusion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FUSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Pharmaceuticals Competitors List
Related Companies and Tools
